Peregrine wins $44M contract; Halozyme touts data;

> Peregrine Pharmaceuticals has won a $44 million Department of Defense contract to test Bavituximab as a therapy for viral hemorrhagic fever infections. Story

> Halozyme says that Chemophase met its primary endpoint in a continuing Phase I/IIa trial for superficial bladder cancer. Report

> Adventrx Pharmaceuticals announced preliminary response rate results from its discontinued Phase II clinical trial of ANX-510, or CoFactor, its folate-based biomodulator of 5-FU for metastatic colorectal cancer. Adventrx release

> AstraZeneca is issuing more bonds to pay off its MedImmune debts. This time, it's an 18-month European issue to the tune of about $790 million; the bonds will be sold to institutions outside the U.S. and trade on the London exchange. Report

> Alabama stuck an $800 million suggested price on its Medicaid fraud case against GlaxoSmithKline and Novartis. Fraud report

> Avastin may have lost its chance to go on the U.K.'s National Health Service formulary, but it's still blowing past sales expectations. Avastin report

> What's a surefire way to win a contest? Keep your opponent from showing up, of course. That's what GlaxoSmithKline is trying to do in the over-the-counter weight-loss market. Report

> It's a watershed moment: Risperdal has gone generic. The Johnson & Johnson antipsychotic med now has copycat competition from Teva Pharmaceutical, which got the final FDA go-ahead yesterday. Risperdal report

> Sangamo BioSciences has reported new work in Nature Biotechnology demonstrating the effectiveness of its zinc finger DNA-binding proteins in immunizing cells in the immune system against HIV. Sangamo report

> The drumbeat of criticism over the impact of flat-line budgets at the NIH on the U.S. research community continues to build. In a recent article for the Star-Ledger, scientists report that original grant funding for projects dropped from 30 percent in 1999 to 12 percent today. Report

Industry Voices: Personalized medicine will drive management and restrictions by health plans. Report

And Finally... Researchers say that caffeine could prove an effective tool to prevent MS. Article